Autopsy report · NCT04439071
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 2 years before it stopped.
- 189 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- PTC Therapeutics
- Sponsor type
- Industry
- Conditions
- Pneumonia; COVID-19; Coronavirus
- Interventions
- PTC299; SOC; Placebo
- Participants
- 189
- Sites
- 41
- Countries
- Australia, Belgium, Brazil, Colombia, France, Mexico, Poland, Portugal, South Africa, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.